| Journal | Drug and alcohol review |
| Study Type | Clinical Study |
| Population | Human participants |
This case highlights a critical public safety issue where synthetic opioids are being sold as cannabis products, creating unexpected opioid dependence in unsuspecting consumers. Clinicians must be aware that patients presenting with opioid withdrawal may have unknowingly consumed potent synthetic opioids marketed as cannabis.
A 22-year-old man with no opioid history presented in withdrawal after regularly vaping a product sold as cannabinoids that tested positive only for protonitazene, a potent synthetic opioid. He required higher than standard buprenorphine doses along with diazepam and olanzapine for withdrawal management, and was successfully transitioned to monthly injectable buprenorphine. This case demonstrates the clinical challenge of managing withdrawal from ultra-potent synthetic opioids that may require modified dosing protocols.
“I’ve seen patients unknowingly consume various adulterants in cannabis products, but this represents a particularly dangerous trend of synthetic opioids being sold as cannabis. This case underscores why comprehensive toxicology testing is essential when clinical presentation doesn’t match the reported substance use history.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is protonitazene and why is it clinically significant?
Protonitazene is a synthetic benzimidazole opioid that acts as a potent μ-receptor agonist, belonging to the nitazene class of drugs. It has been increasingly detected in overdose cases in Australia and poses significant risk due to its high potency and potential for contamination in products sold as cannabis.
How can clinicians identify protonitazene exposure in patients presenting with opioid withdrawal?
Patients may present with opioid withdrawal symptoms despite reporting only cannabis use, as seen in this case where a 22-year-old presented after vaping what he believed were cannabinoids. Standard toxicology screens may not detect nitazenes, requiring specialized testing of blood, urine, and the suspected product.
What dosing considerations are needed when treating protonitazene withdrawal with buprenorphine?
This case demonstrated that higher than expected buprenorphine doses may be required for effective withdrawal management from protonitazene. The patient ultimately required standard adjunctive medications including diazepam and olanzapine alongside buprenorphine treatment.
What treatment approach was successful for long-term opioid dependence management in this case?
The patient was successfully transitioned to outpatient care and received a 300 mg subcutaneous buprenorphine monthly injection for ongoing opioid dependence treatment. This long-acting formulation provides sustained treatment adherence and reduces risk of relapse.
Should clinicians be concerned about nitazene contamination in cannabis products?
Yes, this case highlights the emerging risk of synthetic opioid contamination in products marketed as cannabis. Clinicians should maintain high suspicion for opioid exposure in patients presenting with withdrawal symptoms, even when they report only cannabis use.
